SPI1 and gastric cancer: As previous studies have shown that SPI1 can be used as a key regulator of signal communication in the immune system and is associated with poor prognosis in patients with GC, we investigated whether a signature based on SPI1-related immunomodulators could accurately predict the prognosis of patients.